
Opinion|Videos|January 10, 2025
Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas
Panelists discuss how the sequencing of bispecific therapies in first-line vs later-line settings should be guided by factors such as disease stage, prior treatments, and patient-specific characteristics to optimize therapeutic outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What considerations should guide the sequencing of bispecific therapies in first-line vs later-line settings?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
3
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
4
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
5














































